Abstract
Coping with the immune rejection of allotransplants or autologous cells in patients with an active sensitization towards their autoantigens and autoimmunity presently necessitates life-long immune suppressive therapy acting on the immune system as a whole, which makes the patients vulnerable to infections and increases their risk of developing cancer. New technologies to induce antigen selective long-lasting immunosuppression or immune tolerance are therefore much needed.
Original language | English |
---|---|
Article number | e71981 |
Journal | PLoS ONE |
Volume | 8 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2013 |
Subject classification (UKÄ)
- Neurology
- Surgery